Bayesian Two-Stage Adaptive Design in Bioequivalence

Liu Shengjie, Gao Jun, Zheng Yuling, Huang Lei and Yan Fangrong ()
Additional contact information
Liu Shengjie: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing210009, P.R. China
Gao Jun: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing210009, P.R. China
Zheng Yuling: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing210009, P.R. China
Huang Lei: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing210009, P.R. China
Yan Fangrong: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing210009, P.R. China

The International Journal of Biostatistics, 2020, vol. 16, issue 1, 15

Abstract: Bioequivalence (BE) studies are an integral component of new drug development process, and play an important role in approval and marketing of generic drug products. However, existing design and evaluation methods are basically under the framework of frequentist theory, while few implements Bayesian ideas. Based on the bioequivalence predictive probability model and sample re-estimation strategy, we propose a new Bayesian two-stage adaptive design and explore its application in bioequivalence testing. The new design differs from existing two-stage design (such as Potvin’s method B, C) in the following aspects. First, it not only incorporates historical information and expert information, but further combines experimental data flexibly to aid decision-making. Secondly, its sample re-estimation strategy is based on the ratio of the information in interim analysis to total information, which is simpler in calculation than the Potvin’s method. Simulation results manifested that the two-stage design can be combined with various stop boundary functions, and the results are different. Moreover, the proposed method saves sample size compared to the Potvin’s method under the conditions that type I error rate is below 0.05 and statistical power reaches 80 %.

Keywords: Bayesian two-stage adaptive design; Bioequivalence; Interim analysis; Sample re-estimation strategy; Stop boundary functions (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1515/ijb-2018-0105 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:ijbist:v:16:y:2020:i:1:p:15:n:7

Ordering information: This journal article can be ordered from
https://www.degruyte ... journal/key/ijb/html

DOI: 10.1515/ijb-2018-0105

Access Statistics for this article

The International Journal of Biostatistics is currently edited by Antoine Chambaz, Alan E. Hubbard and Mark J. van der Laan

More articles in The International Journal of Biostatistics from De Gruyter
Bibliographic data for series maintained by Peter Golla ().